Clin Infect DisClin. Infect. DiscidcidClinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America1058-48381537-6591Oxford University Press24488975396782610.1093/cid/ciu053ciu053Articles and CommentariesComparison of Patients Hospitalized With Influenza A Subtypes H7N9, H5N1, and
2009 Pandemic H1N1WangChen1234aYuHongjie5aHorbyPeter W.678aCaoBin9aWuPeng10aYangShigui1112aGaoHainv1112aLiHui9aTsangTim K.10aLiaoQiaohong5GaoZhancheng13IpDennis K. M.10JiaHongyu1112JiangHui5LiuBo9NiMichael Y.10DaiXiahong1112LiuFengfeng5Van KinhNguyen14LiemNguyen Thanh15HienTran Tinh616LiYu5YangJuan5WuJoseph T.10ZhengYaming5LeungGabriel M.10FarrarJeremy J.67817CowlingBenjamin J.10UyekiTimothy M.18LiLanjuan1112Institute of Respiratory Medicine,
Beijing Hospital, National Health and Family Planning
CommissionDepartment of Respiratory Medicine,
Capital Medical UniversityBeijing Institute of Respiratory MedicineBeijing Key Laboratory of Respiratory and Pulmonary Circulation
DisordersDivision of Infectious Disease, Key Laboratory of
Surveillance and Early Warning on Infectious Disease, Chinese
Center for Disease Control and Prevention, Beijing,
ChinaOxford University Clinical Research
Unit–Wellcome Trust Major Overseas Programme, Hanoi,
VietnamCentre for Tropical Medicine,
Nuffield Department of Clinical Medicine, Oxford
University, Oxford, United
KingdomSingapore Infectious Disease InitiativeBeijing Chao-Yang Hospital,
Beijing Institute of Respiratory Medicine, Capital Medical
University, BeijingDivision of Epidemiology and
Biostatistics, School of Public Health, Li Ka Shing Faculty of
Medicine, University of Hong Kong, Hong Kong Special Administrative
RegionCollaborative Innovation Center for Diagnosis and
Treatment of Infectious Diseases, HangzhouState Key Laboratory for Diagnosis and Treatment of
Infectious Diseases, Department of Infectious Diseases, the First
Affiliated Hospital, College of Medicine, Zhejiang
University, HangzhouDepartment of Respiratory and Critical Care
Medicine, Peking University People's Hospital,
Beijing, ChinaNational Hospital for Tropical DiseasesNational Hospital for Pediatrics,
HanoiHospital for Tropical Diseases,
Ho Chi Minh City, VietnamISARIC, Centre for
Tropical Medicine, University of Oxford, Churchill Hospital,
Oxford, United KingdomInfluenza Division,
National Center for Immunization and Respiratory Diseases, Centers for
Disease Control and Prevention, Atlanta,
Georgia
Hospitalization with H7N9 virus infection is associated with older age and chronic heart
disease, and patients have a longer duration of hospitalization than patients with H5N1 or
pH1N1. This suggests that host factors are an important contributor to H7N9 severity.
Background. Influenza A(H7N9) viruses isolated from
humans show features suggesting partial adaptation to mammals. To provide insights into
the pathogenesis of H7N9 virus infection, we compared risk factors, clinical presentation,
and progression of patients hospitalized with H7N9, H5N1, and 2009 pandemic H1N1 (pH1N1)
virus infections.
Methods. We compared individual-level data from
patients hospitalized with infection by H7N9 (n = 123), H5N1 (n = 119; 43
China, 76 Vietnam), and pH1N1 (n = 3486) viruses. We assessed risk factors for
hospitalization after adjustment for age- and sex-specific prevalence of risk factors in
the general Chinese population.
Results. The median age of patients with H7N9 virus
infection was older than other patient groups (63 years; P < .001) and
a higher proportion was male (71%; P < .02). After adjustment
for age and sex, chronic heart disease was associated with an increased risk of
hospitalization with H7N9 (relative risk, 9.68; 95% confidence interval,
5.24–17.9). H7N9 patients had similar patterns of leukopenia, thrombocytopenia, and
elevated alanine aminotransferase, creatinine kinase, C-reactive protein, and lactate
dehydrogenase to those seen in H5N1 patients, which were all significantly different from
pH1N1 patients (P < .005). H7N9 patients had a longer duration of
hospitalization than either H5N1 or pH1N1 patients (P < .001), and the
median time from onset to death was 18 days for H7N9 (P = .002) vs
11 days for H5N1 and 15 days for pH1N1 (P = .154).
Conclusions. The identification of known risk factors
for severe seasonal influenza and the more protracted clinical course compared with that
of H5N1 suggests that host factors are an important contributor to H7N9 severity.
(See the Editorial Commentary by Hui and Hayden on pages 1104–6.)
The emergence of human infections with avian influenza A(H7N9) virus further widens the
spectrum of novel influenza A viruses that currently pose a threat to public health [1]. Although H7N9 virus has not been shown to
transmit efficiently between humans, there are indications that the recently emerged H7N9
viruses are better adapted to replication in mammalian cells than other avian influenza A
viruses and represent a plausible pandemic threat [2, 3]. H7N9 viruses isolated from
human cases have amino acid sequences in the hemagglutinin (HA) protein that are associated
with improved binding to α2–6-linked sialidases that are abundant on human
respiratory epithelial cells, and in the polymerase and other proteins that are associated
with increased virulence and transmissibility in mammals [2–4].
In ferret experiments, H7N9 virus replicates well in the upper respiratory tract following
intranasal inoculation, causes relatively mild illness, and is efficiently transmitted by
direct contact, but less so by respiratory droplets [2, 3, 5]. Intratracheal inoculation of ferrets results in severe pneumonia
and high mortality [6]. In a ferret model,
therefore, H7N9 virus possesses a constellation of features that are intermediate between
highly pathogenic H5N1 viruses and fully adapted but less virulent human influenza A viruses
such as influenza A subtypes H3N2 and pandemic H1N1/2009 (pH1N1).
Despite meeting the criteria for a low pathogenic phenotype in birds, H7N9 virus has caused
severe and fatal disease in humans [7]. However,
the demographic profile of patients with H7N9 virus infection is unusual, with a high median
age and an excess of males [8]. Although this
might be due to age and sex differences in exposures to infected poultry or settings
contaminated by infected poultry, the pattern differs markedly from H5N1 cases, and would
also be consistent with age-dependent biological cofactors contributing to pathogenesis and
disease severity [8]. An assessment of the
clinical severity of human infections with H7N9 virus has concluded that many mild cases may
have occurred and the overall symptomatic case fatality risk is estimated to be
<3% [7]. Understanding the
determinants of the severity of disease due to H7N9 virus infection is important both for
the identification and clinical management of high-risk cases and for the purposes of public
health risk assessment and contingency planning.
To assess whether the H7N9 virus genotype translates into a distinct clinical phenotype in
humans, and to provide insights into the pathogenesis of H7N9 virus infection, we compared
the risk factors, clinical presentation, and progression of patients hospitalized with H7N9,
H5N1, and pH1N1 virus infections.
METHODSSubject Ascertainment
All subjects with influenza virus infection reported in this manuscript were hospitalized
patients. The patients with laboratory-confirmed H7N9 infection were all hospitalized in
China between 25 February and 4 May 2013. The Chinese H5N1 cases represent all
hospitalized cases of laboratory-confirmed H5N1 virus infection detected between 30
November 2003 and 8 February 2012. The Vietnamese H5N1 cases represent all hospitalized
cases of laboratory-confirmed H5N1 virus infection detected between 25 December 2003 and
14 March 2009 [9]. A comparison of the Chinese
and Vietnamese H5N1 cases showed similar demographic characteristics, underlying medical
conditions, and behavioral risk factors (Supplementary Data). Patients with pH1N1 virus infection in China were
ascertained through hospitals designated for the treatment of severe cases. The case
definitions and time periods for ascertaining patients hospitalized with influenza A H5N1,
H7N9, and pH1N1 virus infections are available in the Supplementary Data.
Clinical and laboratory data were abstracted retrospectively from original medical
records for cases of H7N9, H5N1, and pH1N1 virus infections. Laboratory values were
presented as medians with interquartile ranges and were dichotomized into normal or
abnormal based on normal ranges for children and adults (Supplementary Table 1). Because the only subjects aged <29 days were 5
subjects with pH1N1 virus infection, and normal laboratory values are different in
neonates compared with other age groups, we excluded all subjects aged <29 days from
the assessment of laboratory results. We excluded pH1N1 cases from the analysis of signs
and symptoms on admission as the ascertainment process for these cases required the
presence of 1 or more symptoms, many of which were severe.
Ethics Statement
The Chinese National Health and Family Planning Commission determined that the collection
of data from H5N1, H7N9, and pH1N1 cases was part of public health investigations of
emerging influenza outbreaks and was exempt from institutional review board assessment.
The Science and Ethics Committee of the Ministry of Science and Technology of Vietnam
approved the collection of clinical data from Vietnamese subjects with H5N1 virus
infection.
Risk Factors for Hospitalization and Death
To assess the importance of putative risk factors for hospitalization with each influenza
A subtype, we estimated the relative risk of being hospitalized in subjects with and
without risk factors. Data on the prevalence of each risk factor in the general Chinese
population were used as denominators for the risk estimates and to weight (adjust) the
overall relative risk estimates by age and sex. Data on age- and sex-specific population
prevalence were available for coronary heart disease, chronic renal disease, diabetes,
hypertension, smoking, and obesity; age-specific but not sex-specific population
prevalence was available for asthma and chronic obstructive pulmonary disease (COPD)
[10–13]. The definitions for these conditions are shown in the
Supplementary Data. The age- and sex-stratified population prevalence of
chronic heart disease (CHD; excluding isolated hypertension) was estimated from a study
that recorded a prior history of hospitalization with coronary artery disease (A history
of hospitalization for myocardial infarction or a surgical history of coronary balloon
angioplasty, or coronary stent implantation or coronary artery bypass.) [10]. We assumed that the age distribution of
coronary artery disease is a valid proxy for the age distribution of CHD. Where surveys
assessed disease prevalence only in older adults, we assumed that prevalence was zero in
those younger than the lower age limit of the survey. Because we were not able to source
relevant baseline data for Vietnam, we have assumed that the age distribution of chronic
diseases is similar in the Chinese and Vietnamese populations.
Statistical Methods
We compared the characteristic of patients infected by different subtypes using Fisher
exact test or χ2 test for comparing proportions and Wilcoxon signed-rank
test for comparing medians of continuous variables. To evaluate the association between
risk factors and the risk of hospitalization, Poisson regression was used to estimate the
incidence rate ratios associated with each risk factor, adjusted for age and sex. The
association between risk factors and the risk of death among hospitalized cases was
assessed using multivariable logistic regression to estimate the odds ratios associated
with each risk factor, adjusted for age and sex. In both analyses a spline function was
used for age to allow for the possibly nonlinear effect of age on risk.
We used the Kaplan-Meier method to estimate survival curves for death and the
hospitalized fatality risk. We used the same approach to estimate the time to invasive
mechanical ventilation. The censoring time of each recovered or nonventilated patient was
set to 90 days. The 95% confidence intervals (CIs) for the cumulative proportion of
subjects requiring invasive ventilation and with a fatal outcome were estimated using
bootstrapping with 1000 resamples.
We used maximum likelihood to estimate the distribution of the number of days of
hospitalization, and compared alternative parametric distributions including γ,
Weibull, and log-normal distributions, selecting the best parametric distribution on the
basis of the Akaike information criterion.
RESULTS
As of 6 August 2013, 133 laboratory-confirmed influenza A(H7N9) cases have been officially
recorded in mainland China. Among these, 123 requiring hospitalization for medical reasons
were included in this study [7]. Ten
laboratory-confirmed mild cases were excluded [14]. Data were included for 119 patients hospitalized with H5N1 (Vietnam =
76; China = 43), and 3486 patients hospitalized with pH1N1.
The median age of subjects hospitalized with H7N9 was 63 years, compared to 26 years for
H5N1 patients and 25 years for pH1N1 patients (P < .001). A higher
proportion of H7N9 subjects were male compared with H5N1 (P = .019)
or pH1N1 subjects (P = .001). Subjects hospitalized with H7N9 had
the highest prevalence of chronic medical conditions traditionally associated with an
increased risk of severe seasonal influenza disease (Table 1). CHD and diabetes were the commonest medical risk factors
reported among H7N9 patients, and the prevalence of smoking and hypertension was higher in
subjects with H7N9 compared with the other patient groups. Pregnancy was more common in
subjects hospitalized with pH1N1.
Characteristics of Subjects Hospitalized With Influenza A Virus Subtypes H7N9,
H5N1, and pH1N1
Characteristic
H7N9a
H5N1
P Value
pH1N1
P Value
Age, y, median (range)
63 (4–91)
26 (1–75)
<.001
25 (0–100)
<.001
Interval from onset, admission days (IQR)
4 (3–6)
5 (3–6)
.155
4 (3–6)
.244
Male sex
87/123 (71%)
67/119 (56%)
.019
1937/3486 (56%)
.001
Any coexisting chronic medical conditions
42/105 (40%)
11/104 (11%)
<.001
748/3485 (21%)
<.001
Chronic heart disease
12/105 (11%)
1/102 (1%)
.001
147/3457 (4%)
.003
Chronic lung disease
10/105 (10%)
6/100 (6%)
.344
305/3397 (9%)
.849
Chronic renal disease
1/105 (1%)
1/102 (1%)
.984
91/3450 (3%)
.221
Chronic liver disease
5/105 (5%)
1/101 (1%)
.092
27/3478 (1%)
.002
Chronic neurological disease
3/105 (3%)
0/39 (0%)
.166
55/3472 (2%)
.356
Diabetes
18/105 (17%)
1/100 (1%)
<.001
185/3470 (5%)
<.001
Asthma
0/105 (0%)
0/0
NA
102/3442 (3%)
.013
Immune compromise
2/105 (2%)
1/100 (1%)
.586
86/3433 (3%)
.685
Hypertension
51/105 (49%)
2/41 (5%)
<.001
366/3479 (11%)
<.001
Malignancy
6/105 (6%)
1/41 (2%)
.375
92/3468 (3%)
.096
Pregnancy
2/105 (2%)
5/106 (5%)
.246
400/3436 (12%)
<.001
Smoking history
26/105 (25%)
10/88 (11%)
.015
541/3431 (16%)
.02
Obesity (BMI ≥30)
3/45 (7%)
0/10 (0%)
.265
175/2018 (9%)
.623
Any coexisting chronic medical conditions are any of the following: asthma,
diabetes, chronic respiratory disease, chronic heart disease, chronic renal disease,
chronic hepatic (liver) disease, chronic neurological disease, immune compromise
(see Supplementary Data for definitions).
Abbreviations: BMI, body mass index; IQR, interquartile range; pH1N1, 2009
pandemic H1N1 virus.
a Reference group.
Compared with subjects without CHD, the presence of CHD was associated with an increased
risk of hospitalization with H7N9 (relative risk [RR], 9.68; 95% CI, 5.24–17.9;
Table 2). CHD was also a risk factor for
hospitalization with pH1N1 (RR, 16.51; 95% CI, 13.68–19.91). Hypertension was
not associated with an increased risk of hospitalization in any group, whereas a history of
smoking was associated with a reduced risk of hospitalization. Chronic renal disease was
associated with a reduced risk of hospitalization in H7N9 and pH1N1 patients. Once patients
were hospitalized, the odds of death were not significantly increased in subjects with any
of the risk factors examined (Table 3).
Age- and Sex-Adjusted Risk Factors for Hospitalization
Risk Factora
Source of Baseline Prevalence Data
H7N9
H5N1
pH1N1
RR (95% CI)b
RR (95% CI)b
RR (95% CI)b
Asthmac
[12, 15]
NC
NC
1.76 (1.43–2.15)
COPDc (assume zero prevalence aged <40 y)
[11]
0.73 (.35–1.52)
4.25 (1.34–13.48)
1.76 (1.43–2.18)
Diabetes (assume zero prevalence aged <20 y)
[10]
1.11 (.67–1.87)
0.23 (.03–1.67)
1.11 (.94–1.30)
Chronic heart disease (assume zero prevalence aged <20 y)
[10]
9.68 (5.24–17.9)
NC
16.51 (13.68–19.91)
Chronic renal disease (assume zero prevalence aged <18 y)
[13]
0.07 (.01–.54)
NC
0.47 (.37–.58)
Hypertension (assume zero prevalence aged <20 y)
[10]
1.28 (.85–1.91)
0.45 (.10–1.99)
0.63 (.55–.71)
Smokingd
[10]
0.38 (.24–.60)
0.41 (.20–.88)
0.74 (.66–.84)
Obesity (BMI ≥30)c
[10]
1.16 (.36–3.74)
NC
2.42 (2.03–2.88)
Abbreviations: BMI, body mass index; CI, confidence interval; COPD, chronic
obstructive pulmonary disease; NC, not calculable due to insufficient data; RR,
relative risk.
a See the Supplementary Data for definitions.
b Adjusted for cubic spline for age (continuous) and sex where data
were available.
c Sex-specific data not available.
d Restricted to subjects aged ≥20 years only.
Age- and Sex-Adjusted Risk Factors for Death Among Hospitalized
Patients
Risk Factora
H7N9
H5N1
pH1N1
Deathb, OR (95% CI)
Deathb, OR (95% CI)
Deathb,OR (95% CI)
Asthma
NC
NC
0.24 (.06–1.01)
COPD
2.55 (.38–17.20)
0.92 (.12–6.83)
0.98 (.51–1.89)
Diabetes
3.68 (.97–14.03)
NC
0.85 (.51–1.44)
Chronic heart disease
0.96 (.18–5.17)
NC
1.22 (.72–2.08)
Chronic renal disease
NC
NC
1.56 (.86–2.80)
Hypertension
1.06 (.36–3.13)
0.24 (.01–6.92)
0.87 (.58–1.29)
Smoking
0.66 (.20–2.17)
1.23 (.25–5.99)
1.12 (.79–1.60)
Obesity (BMI ≥30)
NC
NC
0.96 (.59–1.56)
Abbreviations: BMI, body mass index; CI, confidence interval; COPD, chronic
obstructive pulmonary disease; NC, not calculable due to insufficient data; OR, odds
ratio.
a See Supplementary Data for definitions.
b Adjusted for cubic spline for age (continuous) and sex.
Signs and symptoms at hospital admission were compared for H7N9 and H5N1 cases. Subjects
with H7N9 virus infection were more likely to report a fever, a productive cough, and
hemoptysis than those with H5N1 virus infection (Table 4). Gastrointestinal symptoms were most common in H5N1 cases.
Signs and Symptoms on Admissiona
Sign or Symptom
H7N9
H5N1
P Value
Fever (temp ≥37.8)
99/105 (94%)
75/102 (74%)
<.001
Any cough
96/105 (91%)
89/106 (84%)
.097
Productive cough
59/104 (57%)
35/94 (37%)
.006
Dry cough
17/105 (16%)
45/94 (48%)
<.001
Yellow sputum
33/105 (31%)
10/61 (16%)
.029
Hemoptysis
25/105 (24%)
5/61 (8%)
.008
Myalgia
21/105 (20%)
12/50 (24%)
.572
Fatigue
38/105 (36%)
9/37 (24%)
.179
Shortness of breath
62/105 (59%)
54/93 (58%)
.889
Gastrointestinal symptoms
15/105 (14%)
17/53 (32%)
.01
Diarrhea
10/105 (10%)
6/50 (12%)
.64
Vomiting
4/105 (4%)
10/54 (19%)
.003
Nausea
6/105 (6%)
7/50 (14%)
.093
Central nervous system symptoms
4/105 (4%)
8/113 (7%)
.285
a Or earliest available time point after admission.
The values of hematological, liver, and renal function tests, and markers of inflammation
on admission are shown in Table 5. H7N9 and
H5N1 patients showed similar patterns of elevated alanine aminotransferase, creatinine
kinase, C-reactive protein, and lactate dehydrogenase, which were all significantly higher
than in pH1N1 patients. Leukopenia and thrombocytopenia were equally common in patients with
H7N9 and H5N1 virus infections, and more common than in those with pH1N1 virus infection.
Lymphopenia was more common in patients with H7N9 compared with H5N1 (88% vs
55%; P < .001), and neutropenia was more common in H5N1 patients.
Neutrophilia was equally common in H5N1 and pH1N1 patients, and least common in H7N9
patients.
a Or earliest available time point after admission.
b Reference group.
The risk of invasive ventilation and death among hospitalized cases by influenza A virus
subtype are shown in Figure 1. The cumulative
proportion of hospitalized subjects requiring invasive ventilation differs between subtypes,
reaching 62% (95% CI, 53%–71%) for H7N9, 54%
(95% CI, 45%–63%) for H5N1, and 17% (95% CI,
15%–18%) for pH1N1. Among those ventilated, the interval from onset to
invasive ventilation was a median of 7 days for both H7N9 and H5N1 cases (P
= .651), and 6 days for pH1N1 cases. The hospitalized case fatality risk was highest
for H5N1 (55%; 95% CI, 47%–64%) and death occurred
earlier, with a median time from onset to death of 11 days for H5N1, compared with 15 days
for pH1N1 patients (P = .154) and 18 days for H7N9
(P = .002). H7N9 patients were hospitalized for a longer duration
than either H5N1 (P < .001) or pH1N1 patients (P <
.001) (Figure 2).
Case fatality risk and invasive ventilation risk in hospitalized patients.
A and B, Case fatality risk by influenza A virus
subtype and day of hospitalization (A) and day of illness onset
(B). C and D, Invasive
ventilation risk by influenza A virus subtype and day of hospitalization
(C) and day of illness onset (D). Abbreviation:
pH1N1, 2009 pandemic H1N1 virus.
Distribution of the number of days of hospitalization for patients with H7N9,
H5N1, and pH1N1.
DISCUSSION
One of the most striking differences in this and other comparative analysis is the high
median age of H7N9 patients [16]. This age
distribution is unlikely to be due to differences in humoral immunity as the prevalence of
neutralizing antibodies to H7N9 virus is probably low in all ages [17–20]. It might
arise either because elderly people are more often exposed to the animal or environmental
reservoir of H7N9 viruses, or because elderly people have a greater propensity to become
infected or severely ill following exposure. After adjusting for the age- and sex-specific
prevalence of chronic illnesses in the general Chinese population, we found that CHD was
associated with an increased risk of hospitalization with H7N9 virus infection (RR, 9.68;
95% CI, 5.24–17.9). The age distribution of H7N9 patients may therefore be
partially explained by an increased propensity in persons with CHD (who are mostly older) to
develop severe disease following infection with H7N9 virus. The overrepresentation of males
among H7N9 patients may also be partially explained by this association, because in China
coronary heart disease is commoner in males than females (male prevalence, 0.74%;
female prevalence, 0.51%) [10]. In
agreement with our results, an age- and sex-matched case control study of 25 H7N9 cases has
reported that the presence of a preexisting chronic medical condition (excluding
hypertension) was associated with H7N9 disease (odds ratio, 5.1; 95% CI,
1.5–16.9) [21]. Although only 11%
of H7N9 patients reported a history of CHD, unrecognized CHD may have been present in some
individuals, and other unmeasured age-related factors, such as impaired innate and
cell-mediated immunity, might also contribute to the observed age distribution of
hospitalized H7N9 cases [17, 22, 23]. H7N9 viruses isolated from humans exhibit a mixed receptor specificity, binding
both α2–6- and α2–3-linked sialidases [3, 4, 20]. H7N9 virus can infect cells of both the upper
and lower respiratory tract of humans and ferrets, and disease in ferrets is more severe
following intratracheal inoculation [5, 6, 20].
This raises the possibility that susceptibility of humans to severe H7N9 disease may be a
consequence of an impaired ability to control virus replication in the lower respiratory
tract.
A history of chronic renal disease was associated with a reduced risk of hospitalization
with H7N9 virus infection, but the number of patients with this condition was small, so this
finding should be interpreted with caution. A history of smoking was associated with a
reduced risk of hospitalization with H7N9, H5N1, and pH1N1 virus infections. This is an
unexpected finding that might be biased by inconsistent definitions and methods of
ascertaining smoking history, which were not standardized in the clinical datasets.
The clinical presentation and laboratory indices at hospital admission are similar for H7N9
and H5N1 patients, except that a productive cough, hemoptysis, lymphopenia, and neutropenia
were more common in H7N9 patients. Neutropenia, thrombocytopenia, and elevated liver enzymes
are common in H5N1 patients and have been associated with more severe outcomes [9, 24–29]. A low absolute
lymphocyte count has been associated with poor outcomes in patients hospitalized with pH1N1,
H5N1, and severe acute respiratory syndrome [9,
30–32]. The hematological and serum chemistry abnormalities suggest
that subjects hospitalized with H7N9 have a severe systemic illness. It remains to be
determined if this is a consequence of severe pneumonia and poor tissue oxygenation or is
the result of an excessive inflammatory response (as is seen with H5N1 virus infection)
[33]. High levels of chemokines and cytokines
have been identified in patients with H7N9 virus infection [20]. Extrapulmonary virus replication is an alternative explanation
for the severity of hospitalized H7N9 cases, but H7N9 virus does not posses the polybasic
amino acid motif at the HA cleavage site normally associated with extrapulmonary virus
replication, and experimental H7N9 virus infection of ferrets has provided little evidence
of systemic replication [2, 34, 35]. H7N9 viral RNA has been detected in the serum, urine, and feces of H7N9
patients but it is not known if this represents viral replication occurring outside of the
respiratory tract [35].
Hospitalized H7N9 patients had a case fatality risk that was intermediate between pH1N1 and
H5N1 patients, and a more protracted clinical course than either H5N1 or pH1N1 patients,
with the longest median time to death and the longest hospitalization. Whether this reflects
the natural history of severe H7N9 virus infection, patient characteristics, or differences
in the clinical management of patients with severe H7N9 compared with H5N1 patients,
including increased frequency of rescue modalities such as extracorporeal membrane
oxygenation, is unknown.
The comparisons we have made are limited by a lack of standardization of the methods of
case ascertainment and inclusion, and of the recording of clinical and other data. As such,
the patients and data included in this study may be subject to unmeasured selection and
information biases and differences in practices over time and between locations. However, we
have tried to minimize these potential biases by restricting our analysis only to
hospitalized subjects and to variables where data were available for a reasonable proportion
of all cases. Although the H5N1 patients from China and Vietnam had very similar demographic
characteristics, underlying medical conditions, and behavioral risk factors, there were some
differences in clinical presentation (Supplementary Data), and we cannot exclude that the clinical phenotype of H5N1
virus infections may be heterogeneous. We used univariate analysis that adjusted for age and
sex to explore possible risk factors for hospitalization with H7N9; interactions effects
were not assessed and the estimated odds ratios and RRs might be confounded by other
unmeasured confounders; as such, these risk factors should not be considered to be causal
without further validation.
In conclusion, this comparative analysis shows that patients hospitalized with H7N9 virus
infection share some risk factors with those hospitalized with pH1N1 infection but have a
clinical profile more closely resembling that of H5N1 patients. The identification in H7N9
patients of known risk factors for severe seasonal influenza and the more protracted
clinical course compared with H5N1 patients suggests that host factors may be an important
contributor to the severity of H7N9 virus infection. This is consistent with the observation
that there have probably been a large number of undetected mild H7N9 virus infections, and
to date the patients with detected mild infection have been predominantly young (mean age,
13 years) [7, 14]. H7N9 virus has recently reemerged in China. People with
chronic medical conditions that are traditionally associated with a higher risk of severe
complications following seasonal influenza virus infection should be targeted for preventive
interventions and for early treatment with antiviral drugs should they develop a respiratory
illness.
Supplementary Data
Supplementary materials are available at Clinical Infectious
Diseases online (http://cid.oxfordjournals.org). Supplementary materials consist of data provided by
the author that are published to benefit the reader. The posted materials are not
copyedited. The contents of all supplementary data are the sole responsibility of the
authors. Questions or messages regarding errors should be addressed to the author.
Supplementary Data
Notes
Acknowledgments. We thank staff members of the Bureau of
Disease Control and Prevention and Health Emergency Response Office of the National Health
and Family Planning Commission and provincial and local departments of health for providing
assistance with administration and data collection; staff members at county-, prefecture-,
and provincial-level CDCs at the provinces where human H7N9, H5N1, and pandemic H1N1 cases
occurred for providing assistance with field investigation, administration, and data
collection. We thank Dr Jian Hua Hu of Zhejiang University for her help in data collection.
We thank staff members of the National Hospital for Tropical Diseases, the National
Pediatric Hospital, and the Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam for
assistance with enrolling patients with H5N1 infection and collection of data.
Disclaimer. The findings and conclusions in this report
are those of the authors and do not necessarily represent the official position of the China
Centers for Disease Control and Prevention or the US Centers for Disease Control and
Prevention. The funding bodies had no role in study design, data collection and analysis,
preparation of the manuscript, or the decision to publish.
Financial support. This study was funded by the US
National Institutes of Health (Comprehensive
International Program for Research on AIDS, grant number
U19 AI51915); the Ministry of Science and
Technology, China (grant number 2012 ZX10004-201);
the National Program for Prevention and Control of human infections by
avian-origin H7N9 influenza A virus (grant number
KJYJ-2013-01); the National Natural Science
Foundation of China (grant numbers 81070005/H0104, 81030032/H19
and 81271840); the National Major S & T Research Projects
for the Control and Prevention of Major Infectious Diseases in China
(grant numbers 2012ZX10004-210, 2012ZX10004–206); the
Technology Group Project for Infectious Disease Control of Zhejiang
Province (grant number 2009R50041); and the
Fundamental Research Funds for the Central Universities. P.
W. H. is supported by the Wellcome Trust (grant numbers
089276/Z/09/Z and 089276/B/09/Z).
Potential conflicts of interest. B. J. C. has received
research funding from MedImmune Inc, and consults for Crucell NV. D. K. M. I. has received
research funding from Hoffmann-La Roche. G. M. L. has received speakers’ honoraria
from HSBC and CLSA. All other authors report no potential conflicts.
All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of
Interest. Conflicts that the editors consider relevant to the content of the manuscript have
been disclosed.
ReferencesGaoRCaoBHuYHuman infection with a novel avian-origin influenza A (H7N9)
virusN Engl J Med201336818889723577628BelserJAGustinKMPearceMBPathogenesis and transmission of avian influenza A (H7N9) virus in ferrets
and miceNature2013501556923842497WatanabeTKisoMFukuyamaSCharacterization of H7N9 influenza A viruses isolated from
humansNature2013501551523842494XiongXMartinSRHaireLFReceptor binding by an H7N9 influenza virus from humansNature2013499496923787694ZhuHWangDKelvinDJInfectivity, transmission, and pathology of human H7N9 influenza in ferrets
and pigsScience2013341183623704376KreijtzJHKroezeEVStittelaarKJLow pathogenic avian influenza A(H7N9) virus causes high mortality in
ferrets upon intratracheal challenge: a model to study intervention
strategiesVaccine2013314995923816392YuHCowlingBJFengLHuman infection with avian influenza A H7N9 virus; an assessment of
clinical severityLancet20133821384523803487CowlingBJJinLLauEHComparative epidemiology of human infections with avian influenza A H7N9
and H5N1 viruses in China—a population-based study of laboratory-confirmed
casesLancet20133821293723803488LiemNTTungCVHienNDClinical features of human influenza A (H5N1) infection in Vietnam:
2004–2006Clin Infect Dis20094816394619435433YangZJLiuJGeJPChenLZhaoZGYangWYPrevalence of cardiovascular disease risk factor in the Chinese population:
the 2007–2008 China National Diabetes and Metabolic Disorders
StudyEur Heart J2012332132021719451ZhongNWangCYaoWPrevalence of chronic obstructive pulmonary disease in China: a large,
population-based surveyAm J Respir Crit Care Med20071767536017575095ZhaoJBaiJShenKSelf-reported prevalence of childhood allergic diseases in three cities of
China: a multicenter studyBMC Public Health20101055120836838ZhangLWangFWangLPrevalence of chronic kidney disease in China: a cross-sectional
surveyLancet20123798152222386035IpDDetection of mild to moderate influenza A/H7N9 infection by China's
national sentinel surveillance system for influenza-like illness: case
seriesBMJ2013346f369323798720National Center for Chronic and Noncommunicable Disease Control and
PreventionReport on chronic disease risk factor surveillance in China2007Beijing: People's Medical Publishing House,CowlingBJJinLLauEHComparative epidemiology of human infections with avian influenza A H7N9
and H5N1 viruses in China: a population-based study of laboratory-confirmed
casesLancet20133821293723803488BaiTZhouJShuYSerologic study for influenza A (H7N9) among high-risk groups in
ChinaN Engl J Med201336823394023718151YangPMaCShiWA serological survey of antibodies to H5, H7 and H9 avian influenza viruses
amongst the duck-related workers in Beijing, ChinaPLoS One20127e5077023226380JiaNde VlasSJLiuYXSerological reports of human infections of H7 and H9 avian influenza
viruses in northern ChinaJ Clin Virol200944225919186101ZhouJWangDGaoRBiological features of novel avian influenza A (H7N9) virusNature2013499500323823727AiJHuangYXuKCase-control study of risk factors for human infection with influenza
A(H7N9) virus in Jiangsu Province, China, 2013Euro Surveill2013182051023827526KedzierskaKValkenburgSADohertyPCDavenportMPVenturiVUse it or lose it: establishment and persistence of T cell
memoryFront Immunol2012335723230439WebsterRGImmunity to influenza in the elderlyVaccine2000181686910689149ShindeVHanshaoworakulWSimmermanJMA comparison of clinical and epidemiological characteristics of fatal human
infections with H5N1 and human influenza viruses in Thailand,
2004–2006PLoS One20116e1480921559080YuHGaoZFengZClinical characteristics of 26 human cases of highly pathogenic avian
influenza A (H5N1) virus infection in ChinaPLoS One20083e298518716658YuenKYChanPKPeirisMClinical features and rapid viral diagnosis of human disease associated
with avian influenza A H5N1 virusLancet1998351467719482437FuruyaHKawachiSShigematsuMSuzukiKWatanabeTClinical factors associated with severity in hospitalized children infected
with avian influenza (H5N1)Environ Health Prev Med20111664821432219KandunINTresnaningsihEPurbaWHFactors associated with case fatality of human H5N1 virus infections in
Indonesia: a case seriesLancet2008372744918706688KandeelAManoncourtSAbd el KareemEZoonotic transmission of avian influenza virus (H5N1), Egypt,
2006–2009Emerg Infect Dis2010161101720587181ToKKHungIFLiIWDelayed clearance of viral load and marked cytokine activation in severe
cases of pandemic H1N1 2009 influenza virus infectionClin Infect Dis201050850920136415HungIFChengVCWuAKViral loads in clinical specimens and SARS manifestationsEmerg Infect Dis2004101550715498155FoxALeNMHorbyPSevere pandemic H1N1 2009 infection is associated with transient NK and T
deficiency and aberrant CD8 responsesPLoS One20127e3153522363665de JongMDSimmonsCPThanhTTFatal outcome of human influenza A (H5N1) is associated with high viral
load and hypercytokinemiaNat Med2006121203716964257BelserJALuXMainesTRPathogenesis of avian influenza (H7) virus infection in mice and ferrets:
enhanced virulence of Eurasian H7N7 viruses isolated from humansJ Virol200781111394717686867HuYLuSSongZAssociation between adverse clinical outcome in human disease caused by
novel influenza A H7N9 virus and sustained viral shedding and emergence of antiviral
resistanceLancet20133812273923726392